降钙素原在慢性阻塞性肺疾病急性加重期指导抗生素使用的价值

摘要
图/表
参考文献
相关文章 (12)

全文: PDF (1304 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨降钙素原（PCT）在慢性阻塞性肺疾病急性加重期（AECOPD）指导抗生素使用的临床价值。方法：收集134例AECOPD患者，随机分为PCT组（47例）、指南组（42例）和经验组（45例），对3组患者临床有效率、医疗总费用、抗生素使用费用、住院天数进行统计学评价。结果：PCT组与指南组在医疗总费
用、抗生素使用费用、住院天数上差异均无统计学意义（P＞0.05），PCT组和指南组在医疗总费用、抗生素使用费用、住院天数分别与经验组比较差异均有统计学意义（均P＜0.05），3组治疗有效率比较差异无统计学意义（P＞0.05）。结论：在AECOPD抗感染治疗情况下，利用PCT检测指导抗生素使用能够有效减少住院总费用、抗生素使用费用并缩短患者住院时间。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	巫天贤
	金雪文
	张叶辉
	黄桔红
	郑雨霖

关键词 ：降钙素原, 慢性阻塞性肺疾病, 急性加重期, 抗生素使用

Abstract：Objective: To investigate the value of procalcitonin (PCT) in guiding antibiotic therapy for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: Totally 134 patients with AECOPD were randomly divided into PCT group (47 cases), Guide group (42 cases) and Experience group (45 cases). Three groups of clinical efficacy, the total medical costs, costs of antibiotic therapy and hospitalization days were statistically analysed. Results: Between the PCT group and the guide group in the total medical costs, costs of antibiotics and hospitalization days had no statistically significant difference (P>0.05). PCT group and guide group in the total medical costs, costs of antibiotics and hospitalization days were statistically significant difference compared with the experience group (P<0.05). There was no significant diference in cases of clinical efficacy among the three groups (P>0.05). Conclusion: PCT detection can effectively reduce the total costs of hospitalization, which can also reduce costs of antibiotic therapy and the duration of hospital stay in the treatment of AECOPD patients.

Key words： procalcitonin chronic obstructive pulmonary disease acute exacerbation antibiotic therapy

收稿日期: 2015-11-12

基金资助:玉环县科技计划项目（201364）。

通讯作者: 金雪文，主任医师，Email：jxw045@163.com。

作者简介: 巫天贤（1969-），男，浙江玉环人，副主任医师。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2016/V46/I4/292

[1] SETHI S. MURPHY T F. Infections in the pathogenesis and course of chronic obstructive pulmonary disease[J]. N Eng J Med, 2008, 359(22): 2355-2365.
[2] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志, 2013, 36(4): 255-264.
[3] CHRIST-CRAIN M, JACCARD-STOLZ D, BINGISSER R, et a1. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: clusterrandomised, single-blinded intervention trial[J]. Lancet. 2004, 363(9409): 600-607.
[4] Global Initiative for Chronic Obstructive Lung Disease.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease[EB/OL].[2012-12-01]. http://www.goldcopd.org/uploads/users/files/GOLDReport—April l12011. pdf.
[5] 唐学义, 郑素歌, 杨志刚. 慢性阻塞性肺疾病急性加重期血清降钙素原水平的变化及临床意义[J]. 医学论坛杂志, 2010, 31(16): 161-162.
[6] MEISNER M, TSCHAIKOWSKY K, HUTZLER A, et a1. Postoperative plasma concertrations of procalcitonin after different types of surgery[J]. Intensive Care Med, 1998, 24(7): 680-684.
[7] 高占成. 降钙素原对诊断慢性阻塞性肺疾病急性加重的应用价值[J]. 中华结核和呼吸杂志, 2013, 36(4): 313-314.
[8] 马健, 蒋爱军. C反应蛋白和降钙素原在急诊重症监护室的应用[J]. 临床肺科杂志, 2013, 18(1): 82-83.
[9] 降钙素原急诊临床应用专家共识组. 降钙素原(PCT)急诊临床应用的专家共识[J]. 中华急诊医学杂志, 2012, 21(9): 944-951.
[10] STOLZ D, CHRIST-CRAIN M, BINGISSER R, et a1. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy[J]. Chest, 2007, 131(1): 9-19.
[11] 刘玉玲, 赵小慧, 张克武, 等. 降钙素原与超敏C-反应蛋白在慢性阻塞性肺疾病急性加重期中的临床意义[J]. 中国煤炭工业医学杂志, 2012, 15(9): 1384-1385.
[12] 常春, 姚婉贞, 陈亚红, 等. 慢性阻塞性肺疾病患者急性加重期血清降钙素原水平的变化及临床意义[J]. 中华结核和呼吸杂志, 2006, 29(7): 444-447.
[13] ROSENBERG S R, KALHAN R. Biomarkers in chronic obstructive pulmonary disease[J]. Transl Res, 2012, 159(4): 228-237.
[14] BAFADHEL M, MCKENNA S, TERRY S, et a1. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers[J]. Am J Respir Crit Care Med, 2011, 184(6): 662-671.
[15] 臧金萍. 动态监测重症肺炎并休克患者血清降钙素原(PCT)水平的临床意义[J]. 中国社区医师: 医学专业, 2011,13(22): 255-256.
[16] POLZIN A, PLETZ M, ERBES R, et a1. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tubercu1osis[J]. Eur Respir J, 2003, 21(6): 939-943.
[17] SCHUETZ P, CHRIST-CRAIN M, THOMANN R, et a1. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract Infections [J]. JAMA, 2009, 302(10): l059-1066.
[18] 龙威, 邓星奇, 谢娟, 等. 血清降钙素原测定在慢性阻塞性肺疾病急性加重期治疗中的意义[J]. 中华急诊医学杂志, 2009, 17(9): 974-977.